Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biogen Idec buys Elan's share of Tysabri for $3.25bn plus royalties

Executive Summary

Biogen Idec Inc. is paying $3.25bn in cash up front to acquire Elan Corp. PLC’s 50% share of the blockbuster multiple sclerosis drug Tysabri (natalizumab) and all related intellectual property.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)
    • Product Purchase

Related Companies